Tenax Therapeutics 3Q 2026: EPS ($0.31) — 10-Q Summary

Tenax Therapeutics reported no product revenue in 3Q 2026. Net loss widened year over year as research and development costs rose, primarily reflecting work on the LEVEL and LEVEL-2 trials; lower selling, general and administrative expenses partly offset the increase.Financial Highlights² Reported…